Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

Breast Cancer Research

Table 1 MTHFR C677T genotype distribution among breast cancers and controls

		Alanine/Alanine		Alanine/Valine		Valine/Valine		Alanine/Valine or Valine/Valine
Group	Number of cases	No. (%)	P value^a (OR, 95% CI)	No. (%)	P value^a (OR, 95% CI)	No. (%)	P value^a (OR, 95% CI)	No. (%)	P value^a (OR, 95% CI)	Valine allele frequency
Controls	233	118 (50.6)		92 (39.5)		23 (9.9)				0.30
All breast cancer	335	140 (41.8)	1.00	162 (48.4)	0.03 (1.5, 1.0–2.1)	33 (9.8)	0.55 (1.2, 0.7–2.2)	195 (58.2)	0.04 (1.43, 1.02–2.00)	0.34
Under 40 breast cancer	203	78 (38.4)	1.00	104 (51.2)	0.01 (1.7, 1.2–2.6)	21 (10.4)	0.39 (1.4, 0.7–2.7)	125 (61.6)	0.01 (1.64, 1.12–2.41)	0.36
Familial and/or bilateral breast cancer	132	62 (47.0)	1.00	58 (43.9)	0.49 (1.2, 0.8–1.9)	12 (9.1)	1.00 (1.0, 0.5–2.1)	70 (53.0)	0.51 (1.16, 0.75–1.76)	0.31

^aFisher's exact test (two-sided) for the relevant genotype using the Alanine/Alanine homozygotes as reference. The odds ratio (OR) and 95% confidence intervals (CI) are shown in parentheses.

ISSN: 1465-542X